ReviewWorld journal of surgical oncology2022
Pulmonary sclerosing pneumocytoma: clinical features and prognosis.
Review in World journal of surgical oncology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 28 citations in OpenAlex.
- Symptomatic Sclerosing Pneumocytoma of Lung: A Diagnostic Challenge with Diverse Morphological Patterns.Iranian journal of pathology · 2026Article
- [Diagnosis and Intraoperative Decision-making in Pulmonary Sclerosing Pneumocytoma with Atypical Imaging Findings: A Case Report and Review of the Literature].Zhongguo fei ai za zhi = Chinese journal of lung cancer · 2026Review
- A novel immunohistochemical staining method of frozen sections improves the intraoperative diagnosis of Sclerosing Pneumocytoma and bronchiolar adenoma.Diagnostic pathology · 2026Article
- Article
- Case Report: Pulmonary sclerosing pneumocytoma mimicking as a neuroendocrine tumor onFrontiers in oncology · 2025Article
- The diagnostic value of CT-guided percutaneous lung biopsy in atypical pulmonary hamartoma and pulmonary sclerosing pneumocytoma.Frontiers in oncology · 2025Article
- Papillary adenoma of the lung: A case report and literature review.Experimental and therapeutic medicine · 2024Article
- Revisiting Pulmonary Sclerosing Pneumocytoma.Clinics and practice · 2024Review
- Pulmonary sclerosing pneumocytoma - rare diagnosis in a Caucasian woman: case report and review of the literature.JRSM open · 2024Article
- Navigating the diagnostic maze: the challenge of sclerosing pneumocytoma in frozen sections.International journal of clinical and experimental pathology · 2024Article
- Pulmonary sclerosing pneumocytoma - approaching a solitary pulmonary nodule and the limitations of risk prediction models.BMJ case reports · 2023Article
- Pulmonary sclerosing pneumocytoma: A potential pitfall mimicking lung adenocarcinoma.GHM open · 2023Article
- Giant pulmonary sclerosing pneumocytoma with potentially malignant biological behavior: a case report and literature review.Annals of translational medicine · 2023Article
- [Recent Advances and Controversies in Minute Pulmonary Meningothelial-like Nodules].Zhongguo fei ai za zhi = Chinese journal of lung cancer · 2023Review
- Treatment and post-operative follow-up of pulmonary sclerosing pneumocytoma: A case report.Annals of medicine and surgery (2012) · 2022Article
- An advanced molecular medicine case report of a rare human tumor using genomics, pathomics, and radiomics.Frontiers in genetics · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPulmonary sclerosing pneumocytoma is a kind of rare benign pulmonary tumor with potential malignancy. The clinical features, risk factors for prognosis, and optimal treatment have not been identified yet. This study aimed to investigate the clinical features and prognosis of pulmonary sclerosing pneumocytoma.
methodsWe retrospectively performed a review of pulmonary sclerosing pneumocytoma patients in West China Hospital from 2009 to 2019. The basic characteristics, treatment regimens, operation detail, postoperative variables, and follow-up time were recorded for each case. Differences in features between patients undergoing lobectomy and segmentectomy were compared. We also performed a case review and summarized reported clinical features in former studies.
resultsAltogether 61 pulmonary sclerosing pneumocytoma patients were retrospectively reviewed. Fifty-six patients were female and 5 were male. The patients' median age was 51 (23-73). Seven (11.48%) patients had smoking history. Twenty tumors were located in the right lung [upper lobe (n = 7), middle (n = 2), and lower (n = 11)] and 41 in the left [upper (n = 12) and lower (n = 29)]. The median tumor size was 2 (0.9-7) cm. Thirty-six (59.02%) patients underwent sublobectomy (segmentectomy or wedge resection) whereas 25 (40.98%) underwent lobectomy. All patients recovered uneventfully, and no perioperative mortality was identified. Sublobectomy showed a trend towards reduced chest tube duration and shorter postoperative hospital stays compared with lobectomy.
conclusionsThe findings showed good prognosis of pulmonary sclerosing pneumocytoma and proved its benign characteristics. Sublobectomy showed advanced efficacy regarding chest tube duration and postoperative hospital stay compared with lobectomy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.